PTC Therapeutics Inc (PTCT)

12.16
0.16 1.30
NASDAQ : Health Care
Prev Close 12.00
Open 12.27
Day Low/High 11.88 / 12.12
52 Wk Low/High 5.27 / 60.93
Volume 623.37K
Avg Volume 1.27M
Exchange NASDAQ
Shares Outstanding 41.24M
Market Cap 494.88M
EPS -4.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Commit To Buy PTC Therapeutics At $8, Earn 26% Annualized Using Options

Commit To Buy PTC Therapeutics At $8, Earn 26% Annualized Using Options

Investors eyeing a purchase of PTC Therapeutics Inc stock, but tentative about paying the going market price of $8.55/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2018 put at the $8 strike, which has a bid at the time of this writing of $1.70.

Biotech Premarket Movers: Seres, PTC, Inovio

Biotech Premarket Movers: Seres, PTC, Inovio

Seres Therapeutics, PTC Therapeutics and Inovio Pharmaceuticals were among the biotech stock movers in premarket trading on Thursday.

PTC Therapeutics Announces Agreement To Acquire Emflaza™ For The Treatment Of Duchenne Muscular Dystrophy In U.S.

PTC Therapeutics Announces Agreement To Acquire Emflaza™ For The Treatment Of Duchenne Muscular Dystrophy In U.S.

- Emflaza is the first treatment approved in the U.S. for DMD patients 5 years and older, regardless of genetic mutation

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The firms all have drugs they want the feds to bend the rules to approve.

Could These 9 Drugs Gain FDA Approval in the Age of Trump?

Could These 9 Drugs Gain FDA Approval in the Age of Trump?

Nine biotech and drug companies want FDA approval, but need changed standards to get it.

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The firms all have drugs they want the feds to bend the rules to approve.

Biotech Premarket Movers: PTC, Teligent, Minerva

Biotech Premarket Movers: PTC, Teligent, Minerva

PTC Therapeutics, Teligent and Minerva Neurosciences were among the biotech stock movers in premarket trading on Monday.

Relative Strength Alert For PTC Therapeutics

Relative Strength Alert For PTC Therapeutics

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Biotech Premarket Movers: Aurinia, Puma, PTC, Juno

Biotech Premarket Movers: Aurinia, Puma, PTC, Juno

Aurinia Pharmaceuticals, Puma Biotechnology, PTC Therapeutics and Juno Therapeutics were among the biotech stock movers in premarket trading on Thursday.

PTC Therapeutics Suffers Cystic Fibrosis Setback, Dimming Hopes for Any U.S. Approvals

PTC Therapeutics Suffers Cystic Fibrosis Setback, Dimming Hopes for Any U.S. Approvals

The latest setback occurred in a phase III study of cystic fibrosis patients, where treatment with ataluren over 48 weeks failed to improve lung function compared to a placebo.

Noteworthy Friday Option Activity: PTCT, UVV, SREV

Noteworthy Friday Option Activity: PTCT, UVV, SREV

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in PTC Therapeutics Inc , where a total volume of 6,944 contracts has been traded thus far today, a contract volume which is representative of approximately 694,400 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 101.6% of PTCT's average daily trading volume over the past month, of 683,330 shares.

PTC Therapeutics Announces Third Annual STRIVE Grant Award Program For Duchenne Muscular Dystrophy

PTC Therapeutics Announces Third Annual STRIVE Grant Award Program For Duchenne Muscular Dystrophy

-Grant Proposals from Nonprofit Patient Advocacy Organizations Due May 31, 2017-

Sarepta Opens Up About Duchenne Drug Launch, Allays Investors' Worst Fears

Sarepta Opens Up About Duchenne Drug Launch, Allays Investors' Worst Fears

There are 250 Duchenne patients starting the process to receive reimbursement and treatment with Exondys 51, Sarepta says.

PTCT Crosses Above Average Analyst Target

PTCT Crosses Above Average Analyst Target

In recent trading, shares of PTC Therapeutics Inc have crossed above the average analyst 12-month target price of $14.17, changing hands for $14.29/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

PTC Therapeutics Provides Corporate Update And Outlines 2017 Strategic Priorities To Maximize The Global Value Of Translarna™ And Advance Its Innovative Pipeline

PTC Therapeutics Provides Corporate Update And Outlines 2017 Strategic Priorities To Maximize The Global Value Of Translarna™ And Advance Its Innovative Pipeline

- Preliminary 2016 Translarna unaudited net sales of approximately $81M, a 140% increase vs. 2015 -

Notable Thursday Option Activity: PTCT, HAIN, MRTX

Notable Thursday Option Activity: PTCT, HAIN, MRTX

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in PTC Therapeutics Inc , where a total of 3,841 contracts have traded so far, representing approximately 384,100 underlying shares. That amounts to about 56.6% of PTCT's average daily trading volume over the past month of 678,305 shares.

Commit To Purchase PTC Therapeutics At $8, Earn 23.8% Using Options

Commit To Purchase PTC Therapeutics At $8, Earn 23.8% Using Options

Investors eyeing a purchase of PTC Therapeutics Inc stock, but tentative about paying the going market price of $11.72/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2018 put at the $8 strike, which has a bid at the time of this writing of $1.90.

PTC Therapeutics Receives France's 2016 Prix Galien For Translarna™

PTC Therapeutics Receives France's 2016 Prix Galien For Translarna™

- Award recognizes scientific innovation of first approved drug for underlying cause of nonsense mutation Duchenne muscular dystrophy -